A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
Status:
Recruiting
Trial end date:
2024-11-04
Target enrollment:
Participant gender:
Summary
VA-BRAVE will determine whether a 28-day long-acting injectable sub-cutaneous (in the belly
area) formulation of buprenorphine at a target dose of 300mg is superior in retaining
Veterans in opioid treatment and in sustaining opioid abstinence compared to the daily
sublingual (under the tongue) buprenorphine formulation at a target dose of 16-24 mg
(standard of care). This is an open-label, randomized, controlled trial including 900
Veterans with opioid use disorder (OUD) recruited over 3 years and followed actively for 52
weeks. There are a number of secondary objectives that will be studied as well and include:
comorbid substance use, both non-fatal and fatal opioid overdose, HIV and Hepatitis C (HCV)
testing results and risk behaviors, incarceration, quality of life, psychiatric symptoms of
depression and posttraumatic stress disorder, housing status, and cost-effectiveness.